These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 10931408

  • 1. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 2. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
    J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
    [Abstract] [Full Text] [Related]

  • 3. [Early diagnosis of Kawasaki disease complicated by coronary artery lesions].
    Hu XH, Xu SX, Luan Z.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):853-5. PubMed ID: 12919919
    [Abstract] [Full Text] [Related]

  • 4. Prognostic impact of vascular leakage in acute Kawasaki disease.
    Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y.
    Circulation; 2003 Jul 22; 108(3):325-30. PubMed ID: 12835221
    [Abstract] [Full Text] [Related]

  • 5. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
    Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.
    J Pediatr; 2000 Aug 22; 137(2):172-6. PubMed ID: 10931407
    [Abstract] [Full Text] [Related]

  • 6. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T.
    J Pediatr; 2004 Apr 22; 144(4):496-9. PubMed ID: 15069399
    [Abstract] [Full Text] [Related]

  • 7. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 22; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 8. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
    Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R.
    J Paediatr Child Health; 2004 Apr 22; 40(9-10):524-9. PubMed ID: 15367145
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin.
    Mori M, Imagawa T, Katakura S, Miyamae T, Okuyama K, Ito S, Nakamura T, Kimura H, Yokota S.
    Mod Rheumatol; 2004 Apr 22; 14(1):43-7. PubMed ID: 17028804
    [Abstract] [Full Text] [Related]

  • 10. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
    Pediatrics; 2005 Dec 22; 116(6):e760-6. PubMed ID: 16322132
    [Abstract] [Full Text] [Related]

  • 11. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease.
    Mitani Y, Sawada H, Hayakawa H, Aoki K, Ohashi H, Matsumura M, Kuroe K, Shimpo H, Nakano M, Komada Y.
    Circulation; 2005 Jan 04; 111(1):38-43. PubMed ID: 15611368
    [Abstract] [Full Text] [Related]

  • 12. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K.
    Eur J Pediatr; 1994 Sep 04; 153(9):663-7. PubMed ID: 7957426
    [Abstract] [Full Text] [Related]

  • 13. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H.
    Arch Dis Child; 2004 Aug 04; 89(8):776-80. PubMed ID: 15269082
    [Abstract] [Full Text] [Related]

  • 14. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.
    Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, Sasakid N.
    Pediatr Res; 2003 Jun 04; 53(6):983-8. PubMed ID: 12621103
    [Abstract] [Full Text] [Related]

  • 15. Intravenous gamma-globulin for Kawasaki disease.
    Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T.
    Acta Paediatr Jpn; 1991 Dec 04; 33(6):799-804. PubMed ID: 1801560
    [Abstract] [Full Text] [Related]

  • 16. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D.
    Arch Dis Child; 2011 Nov 04; 96(11):1088-90. PubMed ID: 20551193
    [Abstract] [Full Text] [Related]

  • 17. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
    Kashef S, Safari M, Amin R.
    Kaohsiung J Med Sci; 2005 Sep 04; 21(9):401-4. PubMed ID: 16248123
    [Abstract] [Full Text] [Related]

  • 18. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
    Lee TJ, Kim KH, Chun JK, Kim DS.
    Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
    [Abstract] [Full Text] [Related]

  • 19. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 31; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 20. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, Iemura M, Ishii M, Kato H.
    Pediatr Int; 1999 Feb 31; 41(1):1-7. PubMed ID: 10200128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.